Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1998 Dec;95(4):631–639. doi: 10.1046/j.1365-2567.1998.00637.x

Characterization of recombinant type II collagen: arthritogenicity and tolerogenicity in DBA/1 mice.

L K Myers 1, D D Brand 1, X J Ye 1, M A Cremer 1, E F Rosloniec 1, M Bodo 1, J Myllyharju 1, T Helaakoski 1, M Nokelainen 1, T Pihlajaniemi 1, K Kivirikko 1, C L Yang 1, L Ala-Kokko 1, D J Prockop 1, H Notbohm 1, P Fietzek 1, J M Stuart 1, A H Kang 1
PMCID: PMC1364363  PMID: 9893056

Abstract

Recombinant human type II collagen (rhCII) was produced using both the HT1080 mammalian cell expression system (rhCIIht) and a baculovirus expression system (rhCIIbac). The biosynthesis of CII requires extensive post-translational modifications, such as the hydroxylation of prolyl and lysyl residues and glycosylation of hydroxylysyl residues. Amino acid analyses indicated that the rhCIIbac was adequately hydroxylated at prolyl residues but underhydroxylated at lysyl residues and underglycosylated compared with tissue-derived hCII, while rhCIIht was hyperhydroxylated and hyperglycosylated at lysyl residues. When the murine collagen-induced arthritis (CIA) model was used to investigate the immunological properties of the two forms of recombinant CII, each induced a high incidence of arthritis following immunization of susceptible mice when emulsified with complete Freund's adjuvant (CFA). However, the severity of the arthritis, as assessed by the number of affected limbs, was significantly higher in mice immunized with rhCIIht than in mice immunized with rhCIIbac. These data indicate that the degree of hydroxylysine glycosylation may play a role in the induction of the arthritogenic response to CII. Each of the recombinant collagens was comparable to tissue-derived hCII in their ability to induce tolerance and suppress arthritis when given as intravenous or oral tolerogens. Taken together, our data suggest that recombinant CII can be prepared in adequate amounts for therapeutic uses and that the material is immunologically comparable to tissue-derived hCII when used to induce tolerance.

Full text

PDF
631

Images in this article

633Figure 1
on p.633

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ala-Kokko L., Hyland J., Smith C., Kivirikko K. I., Jimenez S. A., Prockop D. J. Expression of a human cartilage procollagen gene (COL2A1) in mouse 3T3 cells. J Biol Chem. 1991 Aug 5;266(22):14175–14178. [PubMed] [Google Scholar]
  2. Barnett M. L., Combitchi D., Trentham D. E. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum. 1996 Apr;39(4):623–628. doi: 10.1002/art.1780390413. [DOI] [PubMed] [Google Scholar]
  3. Barnett M. L., Kremer J. M., St Clair E. W., Clegg D. O., Furst D., Weisman M., Fletcher M. J., Chasan-Taber S., Finger E., Morales A. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 1998 Feb;41(2):290–297. doi: 10.1002/1529-0131(199802)41:2<290::AID-ART13>3.0.CO;2-R. [DOI] [PubMed] [Google Scholar]
  4. Chen Y., Inobe J., Weiner H. L. Inductive events in oral tolerance in the TCR transgenic adoptive transfer model. Cell Immunol. 1997 May 25;178(1):62–68. doi: 10.1006/cimm.1997.1119. [DOI] [PubMed] [Google Scholar]
  5. Fertala A., Sieron A. L., Ganguly A., Li S. W., Ala-Kokko L., Anumula K. R., Prockop D. J. Synthesis of recombinant human procollagen II in a stably transfected tumour cell line (HT1080). Biochem J. 1994 Feb 15;298(Pt 1):31–37. doi: 10.1042/bj2980031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Jensen T., Galli-Stampino L., Mouritsen S., Frische K., Peters S., Meldal M., Werdelin O. T cell recognition of Tn-glycosylated peptide antigens. Eur J Immunol. 1996 Jun;26(6):1342–1349. doi: 10.1002/eji.1830260625. [DOI] [PubMed] [Google Scholar]
  7. Khare S. D., Krco C. J., Griffiths M. M., Luthra H. S., David C. S. Oral administration of an immunodominant human collagen peptide modulates collagen-induced arthritis. J Immunol. 1995 Oct 1;155(7):3653–3659. [PubMed] [Google Scholar]
  8. Lamberg A., Helaakoski T., Myllyharju J., Peltonen S., Notbohm H., Pihlajaniemi T., Kivirikko K. I. Characterization of human type III collagen expressed in a baculovirus system. Production of a protein with a stable triple helix requires coexpression with the two types of recombinant prolyl 4-hydroxylase subunit. J Biol Chem. 1996 May 17;271(20):11988–11995. doi: 10.1074/jbc.271.20.11988. [DOI] [PubMed] [Google Scholar]
  9. Michaëlsson E., Malmström V., Reis S., Engström A., Burkhardt H., Holmdahl R. T cell recognition of carbohydrates on type II collagen. J Exp Med. 1994 Aug 1;180(2):745–749. doi: 10.1084/jem.180.2.745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Miller A., Lider O., Roberts A. B., Sporn M. B., Weiner H. L. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):421–425. doi: 10.1073/pnas.89.1.421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Miller E. J. The structure of fibril-forming collagens. Ann N Y Acad Sci. 1985;460:1–13. doi: 10.1111/j.1749-6632.1985.tb51152.x. [DOI] [PubMed] [Google Scholar]
  12. Myers L. K., Stuart J. M., Seyer J. M., Kang A. H. Identification of an immunosuppressive epitope of type II collagen that confers protection against collagen-induced arthritis. J Exp Med. 1989 Dec 1;170(6):1999–2010. doi: 10.1084/jem.170.6.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Nagler-Anderson C., Bober L. A., Robinson M. E., Siskind G. W., Thorbecke G. J. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci U S A. 1986 Oct;83(19):7443–7446. doi: 10.1073/pnas.83.19.7443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Nokelainen M., Helaakoski T., Myllyharju J., Notbohm H., Pihlajaniemi T., Fietzek P. P., Kivirikko K. I. Expression and characterization of recombinant human type II collagens with low and high contents of hydroxylysine and its glycosylated forms. Matrix Biol. 1998 Jan;16(6):329–338. doi: 10.1016/s0945-053x(98)90004-x. [DOI] [PubMed] [Google Scholar]
  15. Sieper J., Kary S., Sörensen H., Alten R., Eggens U., Hüge W., Hiepe F., Kühne A., Listing J., Ulbrich N. Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial. Arthritis Rheum. 1996 Jan;39(1):41–51. doi: 10.1002/art.1780390106. [DOI] [PubMed] [Google Scholar]
  16. Sieron A. L., Fertala A., Ala-Kokko L., Prockop D. J. Deletion of a large domain in recombinant human procollagen II does not alter the thermal stability of the triple helix. J Biol Chem. 1993 Oct 5;268(28):21232–21237. [PubMed] [Google Scholar]
  17. Staines N. A. Oral tolerance and collagen arthritis. Br J Rheumatol. 1991;30 (Suppl 2):40–43. [PubMed] [Google Scholar]
  18. Stuart J. M., Cremer M. A., Dixit S. N., Kang A. H., Townes A. S. Collagen-induced arthritis in rats. Comparison of vitreous and cartilage-derived collagens. Arthritis Rheum. 1979 Apr;22(4):347–352. doi: 10.1002/art.1780220406. [DOI] [PubMed] [Google Scholar]
  19. Tenni R., Rimoldi D., Zanaboni G., Cetta G., Castellani A. A. Hydroxylysine glycosides: preparation and analysis by reverse phase high performance liquid chromatography. Ital J Biochem. 1984 Mar-Apr;33(2):117–127. [PubMed] [Google Scholar]
  20. Trentham D. E., Dynesius-Trentham R. A., Orav E. J., Combitchi D., Lorenzo C., Sewell K. L., Hafler D. A., Weiner H. L. Effects of oral administration of type II collagen on rheumatoid arthritis. Science. 1993 Sep 24;261(5129):1727–1730. doi: 10.1126/science.8378772. [DOI] [PubMed] [Google Scholar]
  21. Weiner H. L., Friedman A., Miller A., Khoury S. J., al-Sabbagh A., Santos L., Sayegh M., Nussenblatt R. B., Trentham D. E., Hafler D. A. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol. 1994;12:809–837. doi: 10.1146/annurev.iy.12.040194.004113. [DOI] [PubMed] [Google Scholar]
  22. Weiner H. L., Mackin G. A., Matsui M., Orav E. J., Khoury S. J., Dawson D. M., Hafler D. A. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science. 1993 Feb 26;259(5099):1321–1324. doi: 10.1126/science.7680493. [DOI] [PubMed] [Google Scholar]
  23. Wooley P. H., Luthra H. S., Krco C. J., Stuart J. M., David C. S. Type II collagen-induced arthritis in mice. II. Passive transfer and suppression by intravenous injection of anti-type II collagen antibody or free native type II collagen. Arthritis Rheum. 1984 Sep;27(9):1010–1017. doi: 10.1002/art.1780270907. [DOI] [PubMed] [Google Scholar]
  24. Yang C. L., Rui H., Mosler S., Notbohm H., Sawaryn A., Müller P. K. Collagen II from articular cartilage and annulus fibrosus. Structural and functional implication of tissue specific posttranslational modifications of collagen molecules. Eur J Biochem. 1993 May 1;213(3):1297–1302. doi: 10.1111/j.1432-1033.1993.tb17881.x. [DOI] [PubMed] [Google Scholar]
  25. van Vollenhoven R. F., Nagler-Anderson C., Soriano A., Siskind G. W., Thorbecke G. J. Tolerance induction by a poorly arthritogenic collagen II can prevent collagen-induced arthritis. Cell Immunol. 1988 Aug;115(1):146–155. doi: 10.1016/0008-8749(88)90169-4. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES